426 related articles for article (PubMed ID: 21511351)
1. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis.
Overgaard J
Radiother Oncol; 2011 Jul; 100(1):22-32. PubMed ID: 21511351
[TBL] [Abstract][Full Text] [Related]
2. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
[TBL] [Abstract][Full Text] [Related]
3. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
4. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
5. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
[TBL] [Abstract][Full Text] [Related]
6. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis.
Lacas B; Bourhis J; Overgaard J; Zhang Q; Grégoire V; Nankivell M; Zackrisson B; Szutkowski Z; Suwiński R; Poulsen M; O'Sullivan B; Corvò R; Laskar SG; Fallai C; Yamazaki H; Dobrowsky W; Cho KH; Beadle B; Langendijk JA; Viegas CMP; Hay J; Lotayef M; Parmar MKB; Aupérin A; van Herpen C; Maingon P; Trotti AM; Grau C; Pignon JP; Blanchard P;
Lancet Oncol; 2017 Sep; 18(9):1221-1237. PubMed ID: 28757375
[TBL] [Abstract][Full Text] [Related]
7. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial.
Horiot JC; Bontemps P; van den Bogaert W; Le Fur R; van den Weijngaert D; Bolla M; Bernier J; Lusinchi A; Stuschke M; Lopez-Torrecilla J; Begg AC; Pierart M; Collette L
Radiother Oncol; 1997 Aug; 44(2):111-21. PubMed ID: 9288839
[TBL] [Abstract][Full Text] [Related]
8. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
[TBL] [Abstract][Full Text] [Related]
9. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer.
Nordsmark M; Overgaard J
Acta Oncol; 2004; 43(4):396-403. PubMed ID: 15303502
[TBL] [Abstract][Full Text] [Related]
10. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J;
Radiother Oncol; 2010 Jan; 94(1):30-5. PubMed ID: 19910068
[TBL] [Abstract][Full Text] [Related]
11. Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck: results of a randomized clinical trial.
Haffty BG; Hurley R; Peters LJ
Cancer J Sci Am; 1999; 5(6):341-7. PubMed ID: 10606475
[TBL] [Abstract][Full Text] [Related]
12. Hyperfractionated or accelerated radiotherapy for head and neck cancer.
Baujat B; Bourhis J; Blanchard P; Overgaard J; Ang KK; Saunders M; Le Maître A; Bernier J; Horiot JC; Maillard E; Pajak TF; Poulsen MG; Bourredjem A; O'Sullivan B; Dobrowsky W; Andrzej H; Skladowski K; Hay JH; Pinto LH; Fu KK; Fallai C; Sylvester R; Pignon JP;
Cochrane Database Syst Rev; 2010 Dec; 2010(12):CD002026. PubMed ID: 21154350
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
14. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial.
Lassen P; Eriksen JG; Krogdahl A; Therkildsen MH; Ulhøi BP; Overgaard M; Specht L; Andersen E; Johansen J; Andersen LJ; Grau C; Overgaard J;
Radiother Oncol; 2011 Jul; 100(1):49-55. PubMed ID: 21429609
[TBL] [Abstract][Full Text] [Related]
15. Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck.
Stausbøl-Grøn B; Overgaard J
Radiother Oncol; 1999 Jan; 50(1):47-55. PubMed ID: 10225557
[TBL] [Abstract][Full Text] [Related]
16. Mature results from a Swedish comparison study of conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN trial.
Zackrisson B; Kjellén E; Söderström K; Brun E; Nyman J; Friesland S; Reizenstein J; Sjödin H; Ekberg L; Lödén B; Franzén L; Ask A; Wickart-Johansson G; Lewin F; Björk-Eriksson T; Lundin E; Dalianis T; Wennerberg J; Johansson KA; Nilsson P
Radiother Oncol; 2015 Oct; 117(1):99-105. PubMed ID: 26427805
[TBL] [Abstract][Full Text] [Related]
17. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.
Poulsen MG; Denham JW; Peters LJ; Lamb DS; Spry NA; Hindley A; Krawitz H; Hamilton C; Keller J; Tripcony L; Walker Q
Radiother Oncol; 2001 Aug; 60(2):113-22. PubMed ID: 11439206
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
PLoS One; 2018; 13(7):e0200137. PubMed ID: 29979726
[TBL] [Abstract][Full Text] [Related]
19. Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: a meta-analysis.
Matuschek C; Haussmann J; Bölke E; Gripp S; Schuler PJ; Tamaskovics B; Gerber PA; Djiepmo-Njanang FJ; Kammers K; Plettenberg C; Anooshahr B; Orth K; Budach W
Radiat Oncol; 2018 Oct; 13(1):195. PubMed ID: 30286777
[TBL] [Abstract][Full Text] [Related]
20. Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck.
Overgaard J; Alsner J; Eriksen J; Horsman MR; Grau C
Rays; 2000; 25(3):313-9. PubMed ID: 11367896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
